BioInfra Life Science Inc. (XKON:266470)

South Korea flag South Korea · Delayed Price · Currency is KRW
306.00
+9.00 (3.03%)
Last updated: Jun 4, 2025
0.66%
Market Cap 5.11B
Revenue (ttm) 1.78B
Net Income (ttm) -3.59B
Shares Out 21.67M
EPS (ttm) -266.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 39
Average Volume 5,519
Open 341.00
Previous Close 297.00
Day's Range 253.00 - 341.00
52-Week Range 180.00 - 580.00
Beta 0.01
RSI 46.70
Earnings Date n/a

About BioInfra Life Science

BioInfra Life Science Inc., a healthcare company, develops cancer gene treatments and technologies that monitor the possibility of metastasis and recurrence in blood for cancer patients in South Korea. Its portfolio includes cancer screening test technology, cancer biomarker research, in-vitro diagnostics medical devices, and targeted drug delivery systems for cancer treatment. The company was founded in 2001 and is based in Seoul, South Korea. [Read more]

Industry Surgical and Medical Instruments and Apparatus
Founded 2001
Country South Korea
Stock Exchange Korea New Exchange
Ticker Symbol 266470
Full Company Profile

Financial Performance

In 2019, BioInfra Life Science's revenue was 1.87 billion, an increase of 20.83% compared to the previous year's 1.55 billion. Losses were -3.28 billion, -13.88% less than in 2018.

Financial Statements

News

There is no news available yet.